Product Description
Merck was developing mk-1496, an oral PLK1 Inhibitor for patients with locally advanced and/or metastatic solid tumors who have failed standard therapy or for whom no standard therapy exists. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00880568)
Mechanisms of Action: PLK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00880568 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-11-01 |